Press Releases

Filter Press Releases:



  • Eli Lilly and Company Unveils Expanded Biotechnology Center in San Diego

    INDIANAPOLIS, June 21, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced completion of a $90 million expansion of its Biotechnology Center in San Diego, California. Lilly's new space will help foster and accelerate the discovery of medicines within the company's core therapeutic areas of immunology, diabetes, oncology and neurodegeneration, as well as the emerging area of pai…

  • Lilly Declares Third-Quarter 2017 Dividend

    INDIANAPOLIS, June 19, 2017 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2017 of $0.52 per share on outstanding common stock. The dividend is payable September 8, 2017, to shareholders of record at the close of business on August 15, 2017. About Eli Lilly and Company Lilly is a global healthcare leader that uni…

  • EULAR 2017: Lilly's Taltz® (ixekizumab) Demonstrated No Progression or Minimal Progression of Radiographic Disease in Patients with Psoriatic Arthritis Through 52 Weeks

    INDIANAPOLIS, June 16, 2017 /CNW/ -- Eli Lilly and Company (NYSE: LLY) announced today that the majority of patients with active psoriatic arthritis (PsA) treated with Taltz® (ixekizumab) exhibited either no progression or minimal progression of radiographic structural joint damage through 52 weeks of treatment. Detailed results from the extension period of the SPIRIT-P1 trial will be presen…

  • New Safety and Long-Term Efficacy Data from Baricitinib Clinical Trials in Patients with Moderate-to-Severe Rheumatoid Arthritis Presented at EULAR 2017

    INDIANAPOLIS, June 16, 2017 /CNW/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announced a new pooled analysis of data from eight Olumiant® (baricitinib) clinical trials, showing that baricitinib-treated and placebo-treated patients with moderate-to-severe rheumatoid arthritis (RA) had similar rates of serious infection incidents. Additionally, new data fr…

  • EULAR 2017: Lilly's Taltz® (ixekizumab) Demonstrated Significant Improvements in Disease Signs and Symptoms at 24 Weeks Among Patients with Active Psoriatic Arthritis Who Had Prior Inadequate Response or Intolerance to TNF Inhibitors

    Taltz also demonstrated significant improvements in key secondary measures at 24 weeks INDIANAPOLIS, June 15, 2017 /CNW/ -- Eli Lilly and Company (NYSE: LLY) announced today that patients with active psoriatic arthritis (PsA) who had inadequate response to one or two TNF inhibitors or were intolerant of TNF inhibitors treated with Taltz® (ixekizumab) achieved significant improvement…

  • Lilly to Present New Data on Olumiant® (baricitinib) in Rheumatoid Arthritis and Taltz® (ixekizumab) in Psoriatic Arthritis at the Annual European Congress of Rheumatology (EULAR 2017)

    INDIANAPOLIS, June 13, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that new data on safety and long-term efficacy from the Olumiant® (baricitinib) clinical trials will be presented in 21 abstracts, including one oral presentation, at the Annual European Congress of Rheumatology (EULAR 2017) in Madrid, June 14-17, 2017. Lill…

  • U.S. FDA Approves Humalog® Junior KwikPen® for the Treatment of Diabetes

    INDIANAPOLIS, June 13, 2017 – The U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company's (NYSE: LLY) Humalog® Junior KwikPen® for the treatment of diabetes. Humalog Junior KwikPen is a prefilled pen with half-unit dosing capability, enabling finer dose adjustment for those who need it. "We are pleased to be able to meet the needs of people who prefer a prefilled insulin…

  • Jardiance® (empagliflozin) analysis reinforces established safety profile

    RIDGEFIELD, Conn., and INDIANAPOLIS, June 13, 2017 /PRNewswire/ -- An analysis of pooled safety data from 19 studies, including the EMPA-REG OUTCOME® trial, involving more than 12,500 adults with type 2 diabetes demonstrated treatment with Jardiance® (empagliflozin) tablets (10 mg or 25 mg) was well tolerated, with no imbalance in lower limb amputations or bone fractures compared with p…

  • Pfizer and Lilly Receive FDA Fast Track Designation for Tanezumab

    Global Phase 3 program is studying potential new treatment option for millions of people living with chronic pain associated with osteoarthritis and chronic low back pain Acts in a different manner than opioids and other analgesics NEW YORK & INDIANAPOLIS--(BUSINESS WIRE)-- Pfizer Inc. (NYSE:PFE) and Eli Lilly and Comp…

  • Jardiance® (empagliflozin) tablets to be studied in chronic kidney disease

    RIDGEFIELD, Conn. and INDIANAPOLIS, June 12, 2017 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced plans to conduct a new, large clinical outcomes trial investigating Jardiance® (empagliflozin) tablets for the treatment of people with chronic kidney disease. The trial will enroll people with chronic kidney disease both with and without type 2 diabete…

  • Lilly's Galcanezumab Significantly Reduces Number of Migraine Headache Days for Patients with Migraine: New Results Presented at AHS

    INDIANAPOLIS, June 10, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today positive results from three Phase 3 studies of galcanezumab, an investigational treatment for the prevention of episodic and chronic migraine, including late-breaking data on several key secondary endpoints for galcanezumab compared to placebo at both studied doses. Detailed results from these studies (E…

  • IDF, in partnership with Lilly, announces second phase of BRIDGES programme funding for translational research in diabetes with focus on secondary prevention

    BRUSSELS and INDIANAPOLIS, June 9, 2017 /PRNewswire/ -- More than 400 million people are living with diabetes. In a further effort to help spread lessons learned from clinical research to benefit people affected by this condition, the International Diabetes Federation (IDF) and Eli Lilly and Company (NYSE: LLY) have come together for the second phase of the Bringing Research in Diabetes to Global…

  • Lilly to Present Late-Breaking Data for Galcanezumab and Lasmiditan at the American Headache Society Annual Scientific Meeting

    INDIANAPOLIS, June 8, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present data from 14 abstracts, including late-breaking Phase 3 data for two investigational treatments for migraine, at the American Headache Society (AHS) annual scientific meeting, taking place June 8-11 in Boston. Lilly will highlight new, Phase 3 primary and secondary endpoint data in three late-breaking pr…

  • Lilly Announces Webcast to Discuss Pain Management Portfolio

    INDIANAPOLIS, June 8, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will conduct a webcast on Monday, June 19, 2017, to discuss the company's pain management portfolio, including data from three Phase 3 studies of galcanezumab, an investigational treatment for the prevention of episodic and chronic migraine, and data from one Phase 3 study of lasmiditan, an investigational treatment for…

  • Lilly Announces Strategic Collaboration with KeyBioscience AG

    STANS, Switzerland and INDIANAPOLIS, June 8, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and KeyBioscience AG have agreed to a new collaboration focused on the development of Dual Amylin Calcitonin Receptor Agonists (DACRAs), a potential new class of treatments for metabolic disorders such as type 2 diabetes, the companies announced today.  The collaboration includes access to the…

  • Derica Rice to Retire as Lilly Chief Financial Officer

    INDIANAPOLIS, June 1, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Derica Rice, executive vice president global services and chief financial officer, will retire at the end of December 2017 after 27 years of service with the company. Rice is also a member of Lilly's executive committee. "On behalf of our shareholders, our board,…

  • Lilly to Participate in Goldman Sachs Global Healthcare Conference

    INDIANAPOLIS, May 31, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the Goldman Sachs 38th Annual Global Healthcare Conference on Wednesday, June 14, 2017. Sue Mahony, Ph.D., senior vice president and president of Lilly Oncology and Levi Garraway, M.D., Ph.D., senior vice president of global development and medical affairs for Lilly Oncology will participate in a fires…

  • Actress Angela Bassett joins For Your SweetHeart™ to urge people with diabetes to know their heart disease risk -- in honor of her mom

    RIDGEFIELD, Conn. and INDIANAPOLIS, May 16, 2017 /PRNewswire/ -- Award-winning actress Angela Bassett, along with 11 leading patient and professional organizations, is joining For Your SweetHeart™: Where diabetes and heart disease meet — a nationwide movement to raise awareness of the critical link between type 2 diabetes and heart disease, the number one killer of people with type 2…

  • Lilly to Participate in Bernstein Strategic Decisions Conference

    INDIANAPOLIS, May 10, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will attend the Bernstein Strategic Decisions Conference on Wednesday, May 31, 2017. David A. Ricks, Lilly's president and chief executive officer, will participate in a fireside chat at 10 a.m., Eastern Time. A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's Investor website…

  • Leigh Ann Pusey Joins Lilly as Senior Vice President of Corporate Affairs and Communications

    INDIANAPOLIS, May 10, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Leigh Ann Pusey will be joining Lilly as senior vice president of corporate affairs and communications, effective June 12, 2017. She will be a member of Lilly's executive committee reporting directly to president and chief executive officer, David A. Ricks. Pusey currently serves as president and…

  • Lilly to Participate in UBS Global Healthcare Conference

    INDIANAPOLIS, May 3, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the UBS Global Healthcare Conference on Tuesday, May 23, 2017. Derica Rice, Lilly's executive vice president for global services and chief financial officer, will participate in a fireside chat at 11 a.m., Eastern Time. A live audio webcast will be available on the "Webcasts & Presentations" section of Lil…

  • Lilly Announces Webcast to Discuss Oncology Pipeline

    INDIANAPOLIS, May 2, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will conduct a webcast on Saturday, June 3, 2017, to discuss the company's oncology pipeline, including data from the MONARCH 2 study of abemaciclib in patients with hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer, which will be presented at the American So…

  • Lilly Declares Second-Quarter 2017 Dividend

    INDIANAPOLIS, May 1, 2017 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2017 of $0.52 per share on outstanding common stock. The dividend is payable June 9, 2017, to shareholders of record at the close of business on May 15, 2017. About Eli Lilly and CompanyLilly is a global healthcare leader that unites caring…

  • Lilly Reports First-Quarter 2017 Results

    INDIANAPOLIS, April 25, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced financial results for the first quarter of 2017.   $ in millions, except per share data First Quarter % 2017 2016 Change Revenue $ 5,228.3 $ 4,865.1 7 % Net Income (Loss) - Reported (110.8)…

  • Lilly Confirms Date and Conference Call for First-Quarter 2017 Financial Results Announcement

    INDIANAPOLIS, April 11, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its financial results for the first quarter of 2017 on Tuesday, April 25, 2017. Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial performance. The conference call will begin at 9 a.m. Eastern time. Investors, media an…

  • Lilly and Ohio University Heritage College of Osteopathic Medicine Partner on Rotation Program for Medical Students

    INDIANAPOLIS, April 4, 2017 /PRNewswire/ -- Students from Ohio University's Heritage College of Osteopathic Medicine will soon join Eli Lilly and Company's (NYSE: LLY) innovative rotation program for aspiring physicians. Launched in early 2014, the program provides students with hands-on experience in a range of pharmaceutical business activities, from drug discovery and development to bioethics…

  • Lilly Announces $850 Million Investment in U.S. Capital Projects in 2017

    INDIANAPOLIS, March 24, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced plans to invest $850 million in its U.S. operations in 2017. The company's investments span facilities across its U.S. enterprise, including research laboratories, manufacturing sites, and general and administrative areas. The investments are being driven by demand for Lilly products, as well as its rob…

  • Lilly Announces Changes in Senior Management

    INDIANAPOLIS, March 2, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced changes in its executive committee. Johna Norton will be promoted to senior vice president of global quality April 1, replacing Fionnuala Walsh, who is retiring April 15 after 28 years at Lilly. Norton currently is vice president, Global Quality for API Manufacturing, Product Research and Developme…

  • Lilly Completes Acquisition of CoLucid Pharmaceuticals

    INDIANAPOLIS, March 1, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of CoLucid Pharmaceuticals, Inc. (NASD:CLCD). The tender offer for all outstanding shares of common stock of CoLucid, at a price of $46.50 per share, expired as scheduled on Tuesday, February 28, 2017. As of the expiration of the tender offer, 17,410,607 sh…

  • Lilly To Present At Leerink Partners Global Healthcare Conference

    INDIANAPOLIS, Feb. 9, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present at the Leerink Partners Global Healthcare Conference on Thursday, February 16, 2017. Enrique Conterno, senior vice president of Lilly and president of Lilly Diabetes and Lilly USA, will participate in a fireside chat at 1:30 p.m., Eastern Time. A live audio webcast will be available on the "Webcasts & Pr…

  • Carolyn R. Bertozzi, Ph.D., Elected to Lilly Board of Directors

    INDIANAPOLIS, Feb. 9, 2017 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has elected Carolyn R. Bertozzi, Ph.D., as a new member, effective Feb. 10, 2017. As a member of Lilly's board, she will serve on the Science and Technology and Public Policy and Compliance Committees of the board. Professor Bertozzi is the Anne T. and Robert M. Bass Professor of Chemistry an…

  • Eli Lilly and Company Sponsors Arthritis Foundation 'Living Your Yes With RA,' an Initiative to Provide Resources for the Rheumatoid Arthritis Community

    INDIANAPOLIS, Oct. 12, 2016 /PRNewswire/ -- Supported by Eli Lilly and Company (NYSE: LLY), the Arthritis Foundation is launching 'Living Your Yes With RA,' a new initiative designed to empower people living with rheumatoid arthritis (RA) by giving them tools, education and resources, allowing them to expect more from their RA treatment - seeking remission or low disease activity as the only acce…

  • Lilly's First Volunteer Teams of 2016 Depart in May for Thailand and Ghana

    INDIANAPOLIS, May 19, 2016 /PRNewswire/ -- A team of Eli Lilly and Company (NYSE: LLY) volunteers from its operations worldwide is on the ground in Thailand, working with a local hospital and health volunteers as part of Lilly's Connecting Hearts Abroad global employee volunteer program. A second team of volunteers will depart next week to serve in Ghana. Nine more teams of Lilly volunteers will…

  • Lilly and United Way Celebrate Deepening Partnership, Community Impact

    INDIANAPOLIS, Nov. 5, 2015 /PRNewswire/ -- Representatives from Eli Lilly and Company (NYSE: LLY) and United Way and its partner agencies gathered today to celebrate the early success of a new partnership approach that includes pairing Lilly teams with United Way agencies and a record gift of $13 million. The results will be shared today from 4-6 p.m. at an Impact Celebration event hosted at the…

  • Diabetes Scholars Foundation Announces 2015 Scholarship Recipients

    ROLLING MEADOWS, Ill. and INDIANAPOLIS, June 25, 2015 /PRNewswire/ -- Attending college is a critical milestone in the lives of many young people. But balancing college life and a full course load while keeping a chronic disease such as diabetes in check can make an exciting time much more challenging. Today, the Diabetes Scholars Foundation (Foundation) announced its 2015 college scholarship rec…

  • Olympian Kris Freeman and NASCAR Driver Ryan Reed to Share Their Courageous Stories with Children Who Have Type 1 Diabetes

    INDIANAPOLIS, June 8, 2015 /PRNewswire/ -- Olympic cross-country skier Kris Freeman and NASCAR XFINITY Series driver Ryan Reed will travel across the U.S. this summer to share their stories of perseverance and triumph as part of the Lilly Camp Care Package (LCCP) program. Kris and Ryan will speak to children at select diabetes summer camps about how type 1 diabetes did not stop them from chasing…

  • Lilly commits 780,000 additional vials of insulin to Life for a Child

    INDIANAPOLIS, June 4, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) has committed another 780,000 vials of insulin to the International Diabetes Federation's Life for a Child program. Life for a Child provides free, life-saving medicine to children living in impoverished communities who otherwise would not have access to the insulin they need. The International Diabetes Federation (IDF) i…

  • Lilly Sends Employees to Serve in Vulnerable Communities around the World

    INDIANAPOLIS, May 27, 2015 /PRNewswire/ -- Marcio Donatelli, a senior marketing associate with the animal health division of Eli Lilly and Company (NYSE: LLY), believes his volunteer work in a healthcare setting in Bangkok, Thailand, will be among the most humbling experiences of his life. "Caring for people in need with respect and dignity is the guiding star for me and my fellow volunteers," sh…

  • Lilly Releases Corporate Responsibility, Global Health Reports

    INDIANAPOLIS, May 4, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today released two new reports that provide a comprehensive overview of the company's corporate responsibility efforts. The reports highlight how Lilly is evolving its approach to corporate responsibility by increasingly leveraging its assets and capabilities in partnership with others to have greater, more sustainable im…

  • Lilly, Bristol-Myers Squibb Restructure Erbitux® (cetuximab) Collaboration in North America

    Full Commercialization Rights Transferred to Lilly INDIANAPOLIS & NEW YORK--(BUSINESS WIRE)-- Eli Lilly and Company (NYSE:LLY) and Bristol-Myers Squibb Company (NYSE:BMY) today announced that the companies have agreed to transfer rights to Erbitux® (cetuximab) in North America, including the U.S., Canada, and Puerto Rico, from Br…